Successful long-term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: a prospective multicentre study

被引：20

作者：

Dreyfus, M. ^{[1
,2
]}

Barrois, D. ^{[3
]}

Borg, J-Y ^{[4
]}

Claeyssens, S. ^{[5
]}

Torchet, M-F ^{[6
]}

Arnuti, B. ^{[7
]}

Pautard, B. ^{[8
]}

机构：

[1] Hop Bicetre, Serv Hematol Biol, F-94270 Le Kremlin Bicetre, France

[2] AP HP, Fac Med Paris Sud, Paris, France

[3] Cap Sante 49, Angers, France

[4] Hop Charles Nicolle, Hematol Lab, Rouen, France

[5] Hop Purpan, Ctr Reg Hemophiles, Toulouse, France

[6] Hop Necker Enfants Malad, Ctr Traitement Hemophiles, Paris, France

[7] Ctr Hosp Gen, Unite Hemovigilance, Valence, France

[8] Ctr Hosp Univ Nord, Serv Oncohemato Pediat, Ctr Accueil & Traitement Enfants & Adolescents He, Amiens, France

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷 / 06期

关键词：

RARE COAGULATION DISORDERS; INTRACRANIAL HEMORRHAGE; PHARMACOKINETICS; PROPHYLAXIS; SAFETY; PLASMA;

D O I：

10.1111/j.1538-7836.2011.04281.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1264 / 1266

页数：3

共 50 条

[1] LONG-TERM SUBSTITUTION WITH FACTOR-XIII-CONCENTRATE IN CONGENITAL FACTOR-XIII-DEFICIENCY
EGBRING, R
ANDRASSY, K
HAVEMANN, K
FUCHS, G
RUF, B
SCHANDER, K
TROBISCH, H
BLUT, 1976, 33 (06): : 367 - 376
[2] Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®
Naderi, Majid
Karimi, Mehran
Hosseini, Maryam Sadat
Moradi, Es'hagh
Shamsizadeh, Morteza
Dorgalaleh, Akbar
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (02): : 635 - 640
[3] Results of long-term prophylaxis in patients with factor XIII (FXIII) deficiency
Konska, A.
Stefanska-Windyga, E.
Baran, B.
Bykowska, K.
Windyga, J.
HAEMOPHILIA, 2012, 18 : 190 - 190
[4] A short half-life of the administered factor XIII (FXIII) concentrates after the first replacement therapy in a newborn with severe congenital FXIII deficiency
Fujii, Noriko
Souri, Masayoshi
Ichinose, Akitada
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) : 592 - 594
[5] Markedly shortened half-life of the administered factor XIII (FXIII) concentrates during first replacement therapy in a newborn with severe congenital FXIII deficiency
Fujii, N.
Souri, M.
Shima, M.
Tomoyasu, C.
Isoda, K.
Ichinose, A.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 373 - 373
[6] Long term two central follow up study on a large group of patients with congenital factor XIII deficiency treated prophylactically with Fibrogammin P®
Naderi, Majid
Karimi, Mehran
Alizadeh, Shaban
Dorgalaleh, Akbar
Eshghi, Peyman
Tabibian, Shadi
Dorgaleleh, Saeed
Bamedi, Taregh
HAEMOPHILIA, 2014, 20 : 107 - 107
[7] Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation
Naderi, Majid
Ahmadinejad, Minoo
Hosseini, Maryam S.
Moradi, Es'hagh
Dorgalaleh, Akbar
Shamsizadeh, Morteza
BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (04) : 276 - 278
[8] BLEEDING TENDENCY, LONG-TERM SUBSTITUTION THERAPY AND FACTOR-XIII DETERMINATION, IN PATIENTS WITH CONGENITAL FACTOR-XIII DEFICIENCY
EMRICH, HG
SEITZ, R
BARTELS, M
KREUZ, W
KRONIGER, A
FICKENSCHER, K
LERCH, L
FUCHS, G
EGBRING, R
THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1262 - 1262
[9] PLATELET AND PLASMA FACTOR XIII LEVELS AFTER REPLACEMENT THERAPY IN SEVERE CONGENITAL FACTOR XIII DEFICIENCY: IS THERE A ROLE FOR FACTOR XIII UPTAKE BY MEGAKARYOCYTES?
Radu, C. M.
Bulato, C.
Campello, E.
Sartorello, F.
Zanon, E.
Milan, M.
Gavasso, S.
Spiezia, L.
Simioni, P.
HAEMATOLOGICA, 2016, 101 : 2 - 2
[10] Recombinant factor VIIa for long-term replacement therapy in patients with congenital factor VII deficiency
Huth-Kuehne, Angela
Rott, Hannelore
Zimmermann, Rainer
Halimeh, Susan
THROMBOSIS AND HAEMOSTASIS, 2007, 98 (04) : 912 - 915

← 1 2 3 4 5 →